Omeprazole Teva Conseil

Omeprazole, the active ingredient in Omeprazole Teva Conseil, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Omeprazole Teva Conseil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole Teva Conseil is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication rates when used with antibiotics. - NSA‑induced gastropathy prophylaxis: lowers the risk of ulcer formation in patients requiring long‑term NSAID therapy.

Adverse reactions to omeprazole are generally dose‑related and may vary in frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually transient and self‑limiting. - Nausea or vomiting: occasional and often resolves with continued therapy. - Abdominal pain or flatulence: mild discomfort in the gastrointestinal tract. - Constipation: infrequent but reported. - Dry mouth: mild xerostomia.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema): require immediate medical attention. - Clostridioides difficile‑associated colitis: may occur with prolonged use. - Low magnesium levels (hypomagnesemia): can lead to muscle cramps or cardiac arrhythmia. - Bone fractures (hip, wrist, spine): reported with long‑term therapy. - Acute interstitial nephritis: renal inflammation requiring discontinuation. - Liver enzyme elevations: indicative of hepatic stress.

When prescribing omeprazole, clinicians should consider several safety aspects: - Assess renal and hepatic function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for drug‑drug interactions, especially with antiplatelet agents. - Monitor long‑term users: periodic evaluation for magnesium levels and bone health. - Pregnancy and lactation: use only if the potential benefit outweighs the risk. - Elderly patients: start at the lowest effective dose and monitor for falls. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs. Awareness of the interaction potential helps optimise therapy.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir or other protease inhibitors: markedly decreased antiviral exposure. - Methotrexate (high dose): increased serum concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring more frequent monitoring. - Digoxin: modest increase in serum levels, watch for signs of toxicity. - Diazepam: enhanced sedation, adjust dose if necessary.